Insights

Insight regarding the utilization of antibody-drug conjugate therapy to treat relapsed/refractory advanced bladder cancer.

Nicole Lamanna, MD, and Nirav N. Shah, MD, discuss the use of BTK inhibitors as targeted therapy for chronic lymphocytic leukemia and recent advancements.

This OncLive Insights features three immune thrombocytopenia experts who share their approach to treating different patient populations, considerations when selecting treatments, and emerging therapies for this condition.

Recommendations for assessing and treating patients with relapsed/refractory B-cell ALL based on more recent data presented at ASH 2021.

Expert oncologists navigate the evolving treatment landscape of advanced or metastatic urothelial carcinoma.

An overview of the role of currently-available and emerging BCMA-targeting therapies in the treatment landscape for multiple myeloma.

David Gerber, MD, and Steven Vernino, PhD, provide a discussion on Lambert-Eaton Myasthenic Syndrome (LEMS), its association with small cell lung cancer, and the available treatment options.

Experts come together to share their perspective on the paradigm of previously treated Ph+ chronic myeloid leukemia.

Approaches to planning treatment for patients with newly diagnosed chronic lymphocytic leukemia, as recommended by healthcare professionals from Memorial Sloan Kettering Cancer Center.

Discussion of recent clinical trial updates in HER2-positive metastatic breast cancer and implications for managing 2 patient case scenarios.

Experts in gastrointestinal cancers review optimal treatment strategies for the management of metastatic colorectal cancer (mCRC).

Expert hematologists provide insight on updates on the role of PI3K inhibitors in the treatment of relapsed/refractory MZL and FL.

Drs Arlene O. Siefker-Radtke and Scott T. Tagawa comment on opportunities for treating metastatic urothelial cancer with FGFR targeted therapies based on current trends in molecular testing and emerging therapies.

Practical perspectives on recent data and FDA approvals supporting novel agents that target EGFR exon 20 insertion mutations in non–small cell lung cancer.

Recommendations for managing HR-positive, HER2-negative metastatic breast cancer with CDK4/6 inhibitors and endocrine therapy.

This OncLive Insights features 3 experts who share their thoughts on how the treatment landscape of advanced NSCLC is evolving through use of comprehensive genetic sequencing to identify actionable biomarkers. They summarize how novel therapeutics which target driver alterations in ALK, ROS, RET, or NTRK can be leveraged to personalize and optimize management of advanced NSCLC, ultimately improving survival outcomes.

Srdan Verstovsek, MD, PhD, and Aaron Gerds, MD, MS, review current treatment strategies and challenges for the management of myelofibrosis and the evolving treatment landscape of the disease.

Through the lens of multidisciplinary management in breast cancer, experts share practical insight on the identification and management of interstitial lung disease.

An overview of neuroendocrine tumors and comprehensive insight on the novel targeted therapies that are improving outcomes for patients.

Key opinion leaders discuss disease management strategies and novel therapeutics in high-risk patients with myelodysplastic syndromes, focusing on therapeutic options and diagnostic criteria.

This OncLive Insights features 3 experts who elucidate treatment advances for patients with Chronic Lymphocytic Leukemia (CLL). Considering both the frontline and relapsed/refractory setting, these key opinion leaders share their perspectives on optimal risk stratification, molecular targets, and sequencing strategies given data from recent clinical trials.

This OncLive Insights features two oncologists who specialize in the treatment of Acute Lymphoblastic Leukemia (ALL). They discuss risk assessment, approaches to treatment of both Philadelphia chromosome positive (Ph+) and Ph- ALL, the factors they consider when choosing a treatment setting (community or tertiary academic center), use of MRD in ALL, sequencing therapies in the relapsed/refractory setting, and the role of CAR T-cell therapy in this patient population.

Considerations for using newer, novel-based combination regimens to treat patients with metastatic colorectal cancer based on strategies explored in recent clinical trials.

Key thought leaders in gastrointestinal oncology build a lively discussion on recent clinical trial updates on immuno-oncology-based combinations for the management of patients with metastatic gastric and gastroesophageal junction cancers and the implications for clinical practice.

Key opinion leaders discuss recent updates in treating relapsed or refractory multiple myeloma.

Recommendations for appropriately managing metastatic colorectal cancer with anti-EGFR therapy based on recent changes to cetuximab dosing.

Recommendations for sequencing therapies for triple-class refractory myeloma with options such as selinexor, belantamab mafodotin, or melflufen.

Experts in hematology and medical oncology, Anthony Mato, MD, MSCE, and Lori A. Leslie, MD, discuss the current therapeutic options available for marginal zone lymphoma and follicular lymphoma and provide key insights into how the recent accelerated approval of umbralisib has impacted the treatment landscape.

Experts in gynecologic oncology review key advances in treating advanced endometrial cancer and the promise of combination immunotherapy-based regimens.